Protein folding, molecule generation and AI-native drug pipelines. The lab bench is going computational.
181 articles
Longevity Biotech Fellowship (LBF) is systematically dismantling the aging process into three engineering paths: bioengineering, biostasis, and replacement. The organization focuses on actionable, scalable solutions rather than theoretical health optimization.
36氪 · 116d ago
Researchers are leveraging AI to significantly reduce the time required to identify effective drugs for neurological conditions like MND. This approach aims to repurpose existing compounds to make treatments more affordable and accessible.
BBC Technology · 120d ago
China's healthcare sector is leveraging AI to reduce early-stage drug design costs. The country is establishing itself as a leader in clinical trials and biotech infrastructure.
Bloomberg Technology · 122d ago
Two AI-based science assistants have demonstrated success in drug-retargeting research. These tools are capable of generating scientific hypotheses, with one model further performing data analysis.
Ars Technica AI · 123d ago
The Shenzhou-21 crew has successfully received supplies from Tianzhou-10, enabling 41 new scientific experiments including world-first human artificial embryo studies in microgravity. The mission focuses on space life sciences, microgravity physics, and atmospheric monitoring.
IT之家 · 125d ago
Metis TechBio, an AI-driven biotech firm for drug delivery and formulation, raised HK$2.1 billion ($270M) in HK IPO. The company will debut on Hong Kong exchange.
Bloomberg Technology · 129d ago
Novo Nordisk agreed to hand over an experimental Parkinson’s disease therapy to a Mark Zuckerberg-backed AI startup. The move aims to accelerate development using AI.
Bloomberg Technology · 131d ago
ByteDance's drug discovery unit, Anew Labs, is presenting AI-designed therapies at international conferences. The Shanghai-based operation with offices in Singapore and San Jose lists 36 core members and features prominent advisors like former Innovent Biologics president Liu Yongjun.
SCMP Technology · 140d ago
Stanford professor James Zou is raising funds at a roughly $1 billion valuation for an AI startup. The company focuses on building AI models to enhance research on the human body.
Bloomberg Technology · 148d ago
AWS launched Amazon Bio Discovery, an AI platform to accelerate early-stage drug discovery in pharma. It enables scientists to design and test novel drugs quickly and securely via complex computations.
The Next Web (TNW) · 156d ago
Nobel laureate David Baker's UW lab receives $7 million from Washington Research Foundation. The funding aims to translate AI-designed proteins from computation to lab and market applications.
GeekWire · 184d ago
Outpost Bio has raised $3.5M to develop AI-driven models of the human microbiome. This complex ecosystem of bacteria, fungi, and microbes influences health, nutrition, and drug responses.
The Next Web (TNW) · 201d ago
An experimental lung disease drug developed with artificial intelligence reportedly reversed biological signs of aging in a study. Its developer says the findings could indicate broader therapeutic applications beyond lung disease.
Bloomberg Technology · 12d ago
Swiss biotech company Aukera Therapeutics is developing a highly selective small-molecule inhibitor targeting the RAPTOR protein. The program combines mTOR expertise with AI-driven drug discovery, although the article provides no disclosed clinical or efficacy results.
钛媒体 · 18d ago
Vijay Pande explains why he left a16z’s roughly $4 billion biotech practice to build the smaller, AI-native VZVC. He argues that biology is moving from discovery toward engineering, while open datasets and lower-cost experimentation are essential for AI to transform medicine.
TechCrunch AI · 21d ago
The article explores how AI-enabled life science, cellular reprogramming, precision medicine, and health monitoring could extend human lifespans and reshape wealth planning and careers. It frames longevity as an economic transformation, with opportunities spanning AI drug discovery, biosensors, synthetic biology, regenerative medicine, and brain-computer interfaces.
虎嗅 · 22d ago
China Life Insurance reported record first-half results and plans to increase investments in AI, chips, biotechnology and other technology sectors. The insurer also aims to become a long-term partner for innovative companies.
SCMP Technology · 22d ago
Mindrank AI CEO Niu Zhangming discusses the company's business strategy and the role of AI in drug discovery. The interview offers insight into how an AI biotech company is positioning itself in the life sciences market.
Bloomberg Technology · 24d ago
As measles cases surge in the US due to declining vaccination rates, researchers are shifting focus to developing therapeutic drugs. These treatments aim to assist those who contract the virus or are medically vulnerable.
Wired · 54d ago
Wanbangde Pharmaceutical's new drug WP107, designed for myasthenia gravis, has received FDA approval for multi-dose escalation clinical trials in the US.
36氪 · 65d ago
The CXO sector in China is experiencing a period of growth as the 'water sellers' for the innovative drug industry. This highlights the infrastructure demand supporting pharmaceutical R&D.
钛媒体 · 65d ago
Body-scanning startup Neko Health, founded by Daniel Ek, has secured $700 million in funding. The company is expanding to New York with high-profile backing from investors like Mark Zuckerberg.
The Next Web (TNW) · 66d ago
Joinn Laboratories highlights the critical role of non-human primate resources in the CXO industry. The company emphasizes that resource control is the key differentiator in the next phase of drug development.
钛媒体 · 66d ago
Major AI companies are aggressively entering the pharmaceutical sector, but the long development cycles of drug discovery are clashing with the short-term expectations of capital markets. This analysis explores the friction between AI's rapid iteration speed and the slow, rigorous nature of medical research.
钛媒体 · 67d ago
Bloomage Biotech has established a new smart manufacturing subsidiary in Tianjin with a registered capital of 10 million RMB. The company focuses on pharmaceutical, cosmetic, and medical device production using bio-based materials.
36氪 · 67d ago
A major scandal involving hundreds of research papers reveals that scientists are using incorrect antibodies, leading to flawed data that potentially undermines AI-driven drug discovery and biological modeling.
虎嗅 · 67d ago
The price of experimental monkeys has risen significantly due to a surge in domestic innovative drug R&D projects in China. Supply remains constrained by long breeding cycles and high attrition rates, with high demand expected to persist through next year.
虎嗅 · 68d ago
NNB Nutrition, a supplier of dietary supplement ingredients, raised nearly 200 million RMB to expand R&D and manufacturing. The company utilizes a multi-technology approach including synthetic biology, chemical synthesis, and plant extraction to serve global brands.
36氪 · 68d ago
The article discusses the medical complexities of treating peripheral T-cell lymphoma (AITL) and the role of emerging CAR-T therapies. It highlights that while CAR-T is a promising frontier, it remains an experimental treatment with significant risks.
虎嗅 · 72d ago
A comprehensive global study led by UBC confirms that mRNA vaccine technology is both highly effective and safe. The research synthesized data from clinical trials and real-world monitoring to validate the long-term performance of this technology.
cnBeta (Full RSS) · 74d ago